Moderna: Omicron Booster Candidate Shows Higher Neutralizing Antibody Response Against Subvariants

By Michael Dabaie

Moderna Inc. said new clinical data on its bivalent Omicron, or BA.1, booster candidate demonstrates significantly higher neutralizing antibody response against Omicron subvariants BA.4/5 compared to the currently authorized booster.

The company said mRNA-1273.214 has now demonstrated significantly higher antibody titers against all tested variants, including Omicron BA.1 and BA.4/5 subvariants, ancestral virus, Alpha, Beta, Delta, and Gamma.

One month after administration in previously vaccinated and boosted participants, a 50 microgram booster dose of mRNA-1273.214 elicited significantly higher neutralizing antibody responses against the Omicron subvariants BA.4 and BA.5 compared to the currently authorized booster.

The new data follows results from June from its ongoing Phase 2/3 study.

Previous results showed a 50 microgram booster dose of mRNA-1273.214 met all pre-specified primary objectives and was generally well tolerated, the company said.

Moderna said it has completed regulatory submissions for mRNA-1273.214 in the European Union, United Kingdom, and Australia, and expects to complete most remaining filings this week

The company said it is simultaneously developing mRNA-1273.222, a bivalent candidate based on BA.4/5, consistent with recent FDA guidance.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

July 11, 2022 08:47 ET (12:47 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.